You just read:

Phase III data show significant reduction in blood glucose with investigational compound empagliflozin* added to metformin or metformin plus sulphonylurea in adults with type 2 diabetes

News provided by

Boehringer Ingelheim

Jun 22, 2013, 11:00 ET